ArticleGlycoconjugate journal2000
Glycoinositolphospholipids from Trypanosoma cruzi induce B cell hyper-responsiveness in vivo.
Article in Glycoconjugate journal, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 6 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The surface of the protozoan Trypanosoma cruzi, the etiologic agent of Chagas' disease, is covered by a dense glycolipid layer, composed mainly by a structurally related family of glycoinositolphospholipids (GIPLs). In the present study we evaluated the in vivo effects of the GIPL on B cell function and immunoglobulin (Ig) secretion. We observed that GIPL injection led to a sustained increase in circulating IgM levels. B cells from GIPL injected mice showed higher response when activated in vitro with either LPS or dextran-conjugated anti-IgD antibodies or purified cytokines. GIPL purified from T. cruzi also showed an adjuvant effect, since this glycophospholipid boosted a polysaccharide-(TNP-Ficoll) induced IgG response. Taken together, our data indicate that T. cruzi-derived GIPL could be at least partially responsible for the remarkable B cell activation observed during T. cruzi acute infection in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.